PRINTER'S NO. 2251

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No.

425

Session of

2019

INTRODUCED BY STEPHENS, BIZZARRO, ROTHMAN, HENNESSEY, BURNS,

MILLARD, SCHMITT, KORTZ, DiGIROLAMO, LONGIETTI, McNEILL,

RYAN, SCHLEGEL CULVER, HILL-EVANS, KINSEY, YOUNGBLOOD,

WHEREAS, Myasthenia gravis is a chronic autoimmune

neuromuscular disorder that causes weakness in the skeletal

muscles responsible for moving the arms and legs and for

breathing; and

WHEREAS, Myasthenia gravis is caused by an error in the

transmission of nerve impulses to the muscles that prompts

weakness in the different muscle groups and can be fatal without

specialized care; and

WHEREAS, Myasthenia gravis causes antibodies to block, alter

or destroy the receptors that release a neurotransmitter called

speech and weakness in the arms, hands, fingers, legs or neck;

and

WHEREAS, The distinctive symptom of myasthenia gravis is

muscle weakness that worsens after periods of activity and

improves with periods of rest; and

WHEREAS, Although myasthenia gravis affects men and women

across all racial and ethnic groups, the disorder most commonly

impacts young adult women under 40 years of age or older men

over 60 years of age; and

WHEREAS, Even though myasthenia gravis can generally be

neuromuscular junction that is impacted by myasthenia gravis;

and

WHEREAS, Findings from a recent NINDS-supported study yielded

conclusive evidence about the benefits of surgery for

individuals suffering from myasthenia gravis who do not have

thymoma; and

WHEREAS, Researchers are exploring better ways to treat

myasthenia gravis by developing new tools to better diagnose

individuals with undetectable antibodies and potential

biomarkers; therefore be it